(VIANEWS) – Shares of DMS IMAGING (BEL 20: DMSIM.BR) dropped by a staggering 28.06% in 21 sessions from €0.03 to €0.02 at 22:09 EST on Wednesday, after three consecutive sessions in a row of losses. BEL 20 is sliding 0.52% to €3,666.07, after two sequential sessions in a row of gains.
About DMS IMAGING
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
Volume
Today’s last reported volume for DMS IMAGING is 135912 which is 3.14% above its average volume of 236229.
More news about DMS IMAGING (DMSIM.BR).
